Evidence map›Paper›PMID 37564999›Full record

ArticleClinical & translational immunology2023

Assessment of antibodies in the upper and lower human respiratory tract at steady state and after respiratory viral infection.

Marios Koutsakos, Jackson S Turner, M Cristina Vazquez Guillamet, Daniel Reynolds, Tingting Lei, Derek E Byers, Ali H Ellebedy, Philip A Mudd

Open access · goldAbstract read
In one paragraph

Article in Clinical & translational immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Waning immunity drives respiratory virus evolution and reinfection.Evolution, medicine, and public health · 2025
    Article
  5. The bronchoalveolar lavage dilution conundrum: an updated view on a long-standing problem.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  6. Article
  7. Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Marios KoutsakosDepartment of Microbiology and Immunology The University of Melbourne at the Peter Doherty Institute for Infection and Immunity Melbourne VIC Australia.ORCID https://orcid.org/0000-0001-9994-9723
Jackson S TurnerDepartment of Pathology and Immunology Washington University School of Medicine Saint Louis MO USA.
M Cristina Vazquez GuillametDivision of Pulmonology and Critical Care, Department of Medicine Washington University School of Medicine Saint Louis MO USA.
Daniel ReynoldsDivision of Pulmonology and Critical Care, Department of Medicine Washington University School of Medicine Saint Louis MO USA.
Tingting LeiDepartment of Pathology and Immunology Washington University School of Medicine Saint Louis MO USA.
Derek E ByersDivision of Pulmonology and Critical Care, Department of Medicine Washington University School of Medicine Saint Louis MO USA.
Ali H EllebedyDepartment of Pathology and Immunology Washington University School of Medicine Saint Louis MO USA.
Philip A MuddCenter for Vaccines and Immunity to Microbial Pathogens Washington University School of Medicine Saint Louis MO USA.
Washington University in St. Louis · USThe University of Melbourne · AU

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Household Respiratory Virus SARS-CoV-2 Transmission and Immunity Sub-Study (HRTS)U01AI144616 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GORDON, AUBREE L, THOMAS, PAUL G. · 2019 to 2025
$43.7M
DYNAMICS AND EVOLUTION OF IMMUNE RESPONSES TO INFLUENZA VIRUSESU01AI150747 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI, ANTIA, RUSTOM NOSHIR · 2020 to 2024
$5.9M
Programming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3M
Structural interrogation of vaccine- and infection-induced B cell responsesR01AI168178 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Goran Bajic · 2022 to 2026
$3.9M
Unraveling Human T Follicular Helper Cell DevelopmentR01AI173203 · NIAID · WASHINGTON UNIVERSITY · PI Philip A Mudd · 2023 to 2026
$2.5M
NCATS NIH HHS UL1 TR002345NIAID NIH HHS R01 AI168178NIAID NIH HHS R01 AI173203NIAID NIH HHS U01 AI141990NIAID NIH HHS U01 AI144616NIAID NIH HHS U01 AI150747
6 · The paper itself

Abstract

Objectives: There is an increasing appreciation for the need to study mucosal antibody responses in humans. Our aim was to determine the utility of different types of samples from the human respiratory tract, specifically nasopharyngeal (NP) swabs obtained for diagnostic purposes and bronchoalveolar lavage (BAL) obtained in outpatient and inpatient settings. Methods: We analysed antibody levels in plasma and NP swabs from 67 individuals with acute influenza as well as plasma and BAL from individuals undergoing bronchoscopy, including five control subjects as well as seven moderately and seven severely ill subjects with a respiratory viral infection. Levels of α2-macroglobulin were determined in BAL and plasma to assess plasma exudation. Results: IgG and IgA were readily detectable in BAL and NP swabs, albeit at different ratios, while IgM levels were low. The total amount of antibody recovered from NP swabs varied greatly between study participants. Accordingly, the levels of influenza HA-specific antibodies varied, and individuals with lower amounts of total Ig in NP swabs had undetectable levels of HA-specific Ig. Similarly, the total amount of antibody recovered from BAL varied between study participants. However, severely ill patients showed evidence of increased plasma exudation, which may confound analysis of their BAL samples for mucosal antibodies. Conclusion: Nasopharyngeal swabs collected for diagnostic purposes may have utility in assessing antibodies from the human nasal mucosa, but variability in sampling should be accounted for. BAL samples can be utilised to study antibodies from the lower respiratory tract, but the possibility of plasma exudation should be excluded.

Indexed as

antibodiesBALmucosal immunitynasopharyngeal swab

Identifiers

PMID37564999
PMCPMC10410120
OpenAlexW4385710930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.